Guardion Health Sciences, Inc. (GHSI): Price and Financial Metrics
GHSI Price/Volume Stats
|Current price||$6.01||52-week high||$10.50|
|Prev. close||$6.43||52-week low||$4.66|
|Day high||$6.20||Avg. volume||22,417|
|50-day MA||$6.00||Dividend yield||N/A|
|200-day MA||$7.14||Market Cap||7.61M|
GHSI Stock Price Chart Interactive Chart >
GHSI Stock Summary
- For GHSI, its debt to operating expenses ratio is greater than that reported by merely 0.41% of US equities we're observing.
- With a year-over-year growth in debt of -100%, GUARDION HEALTH SCIENCES INC's debt growth rate surpasses just 0.02% of about US stocks.
- The volatility of GUARDION HEALTH SCIENCES INC's share price is greater than that of 98.31% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to GUARDION HEALTH SCIENCES INC are GNLN, PATI, FWRD, GSM, and BTG.
- GHSI's SEC filings can be seen here. And to visit GUARDION HEALTH SCIENCES INC's official web site, go to www.guardionhealth.com.
GHSI Valuation Summary
- GHSI's price/sales ratio is 0.7; this is 68.18% lower than that of the median Healthcare stock.
- GHSI's EV/EBIT ratio has moved up 9.7 over the prior 50 months.
Below are key valuation metrics over time for GHSI.
GHSI's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- GHSI has a Quality Grade of D, ranking ahead of 6.18% of graded US stocks.
- GHSI's asset turnover comes in at 0.071 -- ranking 291st of 677 Pharmaceutical Products stocks.
- PBH, TXMD, and NVS are the stocks whose asset turnover ratios are most correlated with GHSI.
The table below shows GHSI's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
Guardion Health Sciences, Inc. (GHSI) Company Bio
Guardion Health Sciences, Inc. provides health care services. It offers, Lumega-Z a medical food formulated to replenish and restore the macular protective pigment. The firm also develops medical devices that measures macular pigment density. The company was founded by Michael Favish in 2009 and is headquartered in San Diego, CA.
Most Popular Stories View All
GHSI Latest News Stream
|Loading, please wait...|
GHSI Latest Social Stream
View Full GHSI Social Stream
Latest GHSI News From Around the Web
Below are the latest news stories about GUARDION HEALTH SCIENCES INC that investors may wish to consider to help them evaluate GHSI as an investment opportunity.
Guardion Health Sciences Announces Financial Results for the Quarter Ended March 31, 2023
Viactiv® Product Line Total Revenue Increased approximately 37% for the Quarter Ended March 31, 2023 as compared to the Quarter Ended March 31, 2022HOUSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financia
Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2022
Viactiv® Product Line Generated Net Revenues of approximately $10.6 Million or 96% of Net Revenues for the Year Ended December 31, 2022HOUSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results f
Guardion Health Sciences Hires Alantra, LLC as its Financial Advisor to Explore Strategic Alternatives to Maximize Stockholder Value
Alantra, LLC is an experienced and successful international healthcare investment banking firmHOUSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, has retained Alantra, LLC (“Alantra”) as its financial advisor to assist w
Guardion Health Sciences, Inc. Regains Compliance With Nasdaq Continued Listing Requirements
HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc (“Guardion” or the “Company”) (NASDAQ: GHSI) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. On January 25, 2022, Nasdaq notified Guardion that its common stock failed to maintain a
Guardion Health Sciences, Inc. Announces 1-for-50 Reverse Stock Split Effective on Pre-Market Opening on January 9, 2023
HOUSTON, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (NASDAQ: GHSI) announced today that it will effect a 1-for-50 reverse split of its common stock effective as of 4:01 p.m. Eastern Time on January 6, 2023. Commencing with the opening of trading on the Nasdaq Capital Market on January 9, 2023, the Company’s common stock will trade on a post-split basis under the same symbol GHSI. The reverse stock split was approved by the Company’s stockholder
GHSI Price Returns
Loading social stream, please wait...